| Literature DB >> 24736996 |
Tetsuo Shiohara1,2, Yukiko Ushigome1, Yoko Kano1, Ryo Takahashi3.
Abstract
A growing number of cells, mediators, and pathways have been implicated in severe drug eruptions. Fifteen years ago, we published landmark studies that sparked the current advances in our understanding of the role of viral reactivations in severe drug eruptions. Viral reactivations then became critically important as diagnostic tools, but how precisely they participated in the pathogenesis remained less well-defined. The question of whether viral reactivations are pathogenic or are instead as epiphenomenon of severe tissue damage has plagued the field of drug allergy for some decades. Recent evidence points to a crucial role for tissue-resident memory T (TRM) cells in immune protection against viral infections. Yet immune protection against viral infections is but one side of a coin, the other side of which comprises effector cells capable of mediating severe immunopathology: Once drug antigen is cross-recognized by these T cells, they could be activated to kill surrounding epidermal cells, resulting in drug-induced tissue damage. Such TRM cells could persistently reside in the skin lesions of fixed drug eruptions (FDE) and are most likely a major cell type responsible for the development of FDE. We also discuss the role of regulatory T (Treg) cells in the setting of drug allergy, in which herpesviruses are reactivated in sequence. Although many details of the complicated interactions among viruses, anti-viral immune responses, TRM cells, and Treg cells remain to be elucidated, we review the current status of this rapidly advancing field.Entities:
Keywords: Drug-induced hypersensitivity syndrome; Fixed drug eruption; Graft-versus-host disease; Herpesviruses; Immune reconstitution syndrome; Regulatory T cells; Resident memory T cells
Mesh:
Year: 2015 PMID: 24736996 DOI: 10.1007/s12016-014-8421-3
Source DB: PubMed Journal: Clin Rev Allergy Immunol ISSN: 1080-0549 Impact factor: 10.817